[166Dy]dysprosium/[166Ho]holmium in vivo generator.
A novel approach for the delivery of 166Ho (t1/2 = 26.6 h) to tissue is via the in vivo decay of its 81.5 h parent, 166Dy-an in vivo generator system. A critical question for the in vivo 166Dy/166Ho generator system is whether translocation of the daughter nucleus occurs. The in vitro and in vivo integrity of the [166Dy]Dy/166Ho-DTPA complex was investigated and results indicated that no translocation of the daughter nucleus occurs subsequent to beta- decay of 166Dy. Biodistribution studies of [166Dy]Dy-DTPA showed that the ratio of 166Dy/166Ho in bone remains constant (+/- 7%) over a 20 h period, indicating no significant in vivo loss of 166Ho from the complex. Increasing the in vivo residence time of [166Dy]Dy-DTPA complex attached to HSA gave similar results.
Smith
S V
SV
Biomedicine and Health Program, Australian Nuclear Science and Technology Organisation (ANSTO), New South Wales.
Di Bartolo
N
N
Mirzadeh
S
S
Lambrecht
R M
RM
Knapp
F F
FF
Hetherington
E L
EL
D000818:Animals; D001853:Bone Marrow / Q000378:metabolism*; D001842:Bone and Bones / Q000378:metabolism; D004419:Dysprosium / Q000493:pharmacokinetics*; D006695:Holmium / Q000493:pharmacokinetics*; D006801:Humans; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011868:Radioisotopes / Q000493:pharmacokinetics; D012709:Serum Albumin / Q000493:pharmacokinetics; D014018:Tissue Distribution
D009942:Organometallic Compounds; D011868:Radioisotopes; D012709:Serum Albumin; D004419:Dysprosium; D004369:Pentetic Acid; C055865:dysprosium DTPA; D006695:Holmium